Professor Robert Jones
Professor and Consultant in Medical Oncology
- robert.hugh.jones@wales.nhs.uk
- +44 (0)29 2087 9035
- Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX
- Media commentator
Overview
I am currently Specialty Lead for Cancer in Wales, Early Phase Trials Lead, and Clinical Director of Research at Velindre Cancer Centre. I arrived in Cardiff in 2009, having carried out a Clinician Scientist Post following my Medical Oncology training at the Beatson in Glasgow.
I set up Wales's only Cancer Phase 1 Trials Unit and opened its first ever First in Human Trial and led Global recruitment on it. Having evolved from a zero starting point we now have a team of around 20 staff. I have been Principal Investigator of around 30 Early Phase Trials and I am Chief Investigator on two Investigator Led National Portfolio trials, FAKTION and FURVA. FURVA was reported at the European Society of Medical Oncology meeting (2020) and FAKTION at the American Society of Clinical Oncology (Chicago 2019, and 2022). FAKTION received significant media coverage https://www.youtube.com/watch?v=4DkiQaKzAIg&feature=youtu.be
Biography
I am dual trained in Medicine and Science. I carried out my medical degree in Oxford and then trained as a Medical Oncologist in Glasgow. I completed my PhD in Nic Jones’s laboratory in London, and have carried out short research spells with Paul Russell and Frank McCormick in California. I was appointed as a Consultant Senior Lecturer in Medical Oncology in Bristol in 2003 and obtained a CRUK Clinician Scientist Fellowship in 2005, carrying this out in Alan Clarke’s laboratory in Cardiff. I eventually made a permanent move to Cardiff in 2009.
Publications
2022
- Jones, R. et al. 2022. A Phase I/II trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clinical Cancer Research, article number: CCR-22-2074. (10.1158/1078-0432.CCR-22-2074)
- Saad, F. et al. 2022. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology 23(10), pp. 1297-1307. (10.1016/S1470-2045(22)00498-3)
- Banerjee, S. et al. 2022. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clinical Cancer Research 22, article number: 1268. (10.1158/1078-0432.CCR-22-1268)
- Howell, S. J. et al. 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23(7), pp. 851-864. (10.1016/s1470-2045(22)00284-4)
2021
- Seligmann, J. F. et al. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39(33), pp. 3705-3715. (10.1200/JCO.21.01435)
- Arana Echarri, A. et al. 2021. A phenomic perspective on factors influencing breast cancer treatment: integrating aging and lifestyle in blood and tissue biomarker profiling. Frontiers in Immunology 11, article number: 616188. (10.3389/fimmu.2020.616188)
2020
- Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)
- Hong, D. S. et al. 2020. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 26(6), pp. 1220-1228. (10.1158/1078-0432.CCR-19-2962)
- Peltola, K. J. et al. 2020. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 6(1), pp. 63-70. (10.1016/j.euf.2018.08.022)
2019
- de Bono, J. S. et al. 2019. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncology 20(3), pp. 383-393. (10.1016/S1470-2045(18)30859-3)
2018
- Basu, B. et al. 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29(9), pp. 1918-1925. (10.1093/annonc/mdy245)
- Clarke, N. et al. 2018. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology 19(7), pp. 975-986. (10.1016/S1470-2045(18)30365-6)
2017
- Garcia Martin, I., Janssen, A., Jones, R., Grimstead, J. W., Penketh, R. J. A., Baird, D. M. and John, R. M. 2017. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. Placenta 59, pp. 61-68. (10.1016/j.placenta.2017.09.007)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)
2016
- Reza, M. et al. 2016. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus 2(5), pp. 547-552. (10.1016/j.euf.2016.01.005)
2014
- Fizazi, K. et al. 2014. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 15(9), pp. 975-985. (10.1016/S1470-2045(14)70240-2)
- Greenow, K. R., Clarke, A. R., Williams, G. T. and Jones, R. 2014. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33, pp. 4089-4096. (10.1038/onc.2013.371)
2009
- Greenow, K. R., Clarke, A. R. and Jones, R. H. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28(11), pp. 1443-1453. (10.1038/onc.2008.482)
2006
- Robinson, H. M. R., Jones, R. H., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25(39), pp. 5359-5369. (10.1038/sj.onc.1209532)
2004
- Jones, R. H., Reubi, J., Millan, D. and Vasey, P. 2004. Octreotide: an active agent in epithelial ovarian carcinoma?. The Lancet Oncology 5(4), pp. 251-253. (10.1016/S1470-2045(04)01430-5)
2003
- Jones, R. H. and Vasey, P. A. 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4(12), pp. 738-747. (10.1016/S1470-2045(03)01279-8)
- Jones, R. H., Goldstein, D., Kurtovic, J., Keogh, G. and Riordan, S. M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98(5), pp. 1211-1213. (10.1016/S0002-9270(03)00170-9)
- Jones, R. H., Ryan, M. and Friedlander, M. 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89(1), pp. 112-115. (10.1016/S0090-8258(03)00066-0)
- Jones, R. H. and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39(2), pp. 147-156. (10.1016/S0959-8049(02)00612-3)
2001
- Twelves, C. and Jones, R. H. 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?. Expert Opinion on Pharmacotherapy 2(9), pp. 1495-1505. (10.1517/14656566.2.9.1495)
1990
- Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R. and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10(13), pp. 5610-5621.
1989
- Jones, R. and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86(7), pp. 2176-2180.
1988
- Jones, R., Moreno, S., Nurse, P. and Jones, N. C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53(4), pp. 659-667. (10.1016/0092-8674(88)90581-8)
